Company: NuroKor Bioelectronics
Founder: Rick Rowan
About NuroKor Bioelectronics
Inspired by his own decades-long struggle with chronic pain, Rick Rowan founded NuroKor Bioelectronics in 2018 to pioneer research and product development in the field of bioelectronics. In 2022, development began on Mihna, a breakthrough solution for the management of the symptoms of period pain and endometriosis.
Pain conditions affect millions of women in the UK: around 80% of women will experience period pain during their lifetime, with symptoms ranging from backache to intense abdominal cramps. 10% of women suffer with endometriosis, a condition which can cause excruciating pain and disruption to everyday life.
Despite this, research into the causes of, and treatments for, female pain have been neglected for years. Few options exist for women aside from over-the-counter painkillers: the NuroKor team believe that it’s time this changed.
NuroKor are committed to playing a part in closing the gender pain gap. Their goal is to provide a reliable, effective, drug-free solution that can help reduce the disruption to daily life, loss of work hours and inequality faced by so many women.
Following extensive research, they’re preparing to launch Mihna, a mobile app that works with an ultra wearable device to deliver personalised treatments to target the painful symptoms of period pain and endometriosis.
Mihna serves as a therapeutic by utilising a unique combination of 3 forms of electrical stimulation, developed into user-friendly treatment modes that can be selected using the Mihna mobile app.
The treatments are deployed by the miniature device and delivered by a set of electrode pads that can be integrated into wearable accessories/garments or positioned independently in areas around the back and abdomen. The electrode pads deliver treatment through the surface of the skin, mimicking the body’s own electrical signals and reducing the severity of pain sensations.
The usage data and feedback collected by the mobile app allows for personalisation to treat each woman as an individual.
In parallel with product development, the NuroKor team is committed to building a global community who will contribute directly to life-changing research.
Data Bridge Market Research analysis valued the Global Menstrual Cramps Treatment Market at $4.3 billion in 2021. With a CAGR of 8.3% in the forecast period of 2021 to 2029, this market is expected to reach $8.2 billion by 2029.
Across the seven major markets (7MM), the Global Endometriosis Market is expected to grow from $1.06bn in 2020 to reach $2.42bn by 2026.
Valued at $2.09 billion in 2020, the Global Postpartum Recovery Market is expected to expand at a CAGR of 6.4% from 2021 to 2028.